Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY25 results · Apr–Jun 2024
Eris Lifesciences reported revenue from operations of ₹719.72 crore (up 54.2% from Q1 FY24) and net profit of ₹89.42 crore (down 4.5% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 719.72 | 466.62 | +54.2% | 550.92 | +30.6% |
| Other income | 1.64 | 0.99 | +65.8% | 15.15 | −89.2% |
| Total income | 721.36 | 467.61 | +54.3% | 566.07 | +27.4% |
| Profit before tax | 115.32 | 112.48 | +2.5% | 76.65 | +50.5% |
| Net profit for the period | 89.42 | 93.65 | −4.5% | 79.63 | +12.3% |
| Attributable to shareholders of the company | 83.18 | 94.86 | −12.3% | 70.96 | +17.2% |
| EPS, basic (₹) | 6.11 | 6.97 | −12.3% | 5.22 | +17.0% |
| Net margin (%) | 12.4 | 20.1 | 14.5 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 456.69 | 411.29 | +11.0% | 341.30 | +33.8% |
| Other income | 5.16 | 4.03 | +28.2% | 20.39 | −74.7% |
| Total income | 461.85 | 415.31 | +11.2% | 361.69 | +27.7% |
| Profit before tax | 26.82 | 132.52 | −79.8% | 41.75 | −35.8% |
| Net profit for the period | 17.04 | 110.74 | −84.6% | 39.51 | −56.9% |
| EPS, basic (₹) | 1.25 | 8.14 | not comparable | 2.90 | not comparable |
| Net margin (%) | 3.7 | 26.9 | 11.6 |
Consolidated
- Filed with BSE
- 05 Aug 2024, 13:02 IST
- Board meeting
- 02 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2024, 13:02 IST
- Board meeting
- 02 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE